Ishita Drugs & Indus Stock Screener | Share Price & Fundamental Analysis
ISHITADR
Pharmaceuticals
Screen Ishita Drugs & Indus share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹75.10
▼
-0.88 (-1.16%)
Market Cap
₹23.74 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
2.01
EPS (TTM)
₹2.90
Dividend Yield
-
Debt to Equity
0.19
52W High
₹89.42
52W Low
₹70.00
Operating Margin
7.00%
Profit Margin
5.56%
Revenue (TTM)
₹18.00
EBITDA
₹2.00
Net Income
₹1.00
Total Assets
₹16.00
Total Equity
₹11.00
Ishita Drugs & Indus Share Price History - Stock Screener Chart
Screen ISHITADR historical share price movements with interactive charts. Analyze price trends and patterns.
Ishita Drugs & Indus Company Profile - Fundamental Screener
Screen Ishita Drugs & Indus company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ISHITADR shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE806D01016
Ishita Drugs & Indus Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen ISHITADR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 16 | 11 | 11 | 11 | 9 | 10 | 8 | 7 | 7 | 8 |
| Current Assets | 15 | 10 | 10 | 10 | 8 | 8 | 7 | 6 | 6 | 7 |
| Fixed Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Liabilities | ||||||||||
| Total Liabilities | 16 | 11 | 11 | 11 | 9 | 10 | 8 | 7 | 7 | 8 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 6 | 6 | 6 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | 8 | 7 | 6 | 6 | 5 | 4 | 3 | 3 | 3 | 3 |
Screen ISHITADR income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18 | 15 | 16 | 12 | 14 | 14 | 15 | 9 | 7 | 7 | 7 | 8 |
| Expenses | 16 | 14 | 14 | 11 | 13 | 13 | 14 | 9 | 6 | 6 | 7 | 7 |
| EBITDA | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
| Operating Profit % | 7.00% | 7.00% | 6.00% | 6.00% | 8.00% | 7.00% | 5.00% | 6.00% | 7.00% | 6.00% | 4.00% | 4.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| EPS | 3.20 | 2.90 | 2.50 | 1.93 | 2.69 | 2.77 | 1.83 | 1.18 | 0.83 | 0.61 | 0.46 | 0.74 |
Ishita Drugs & Indus Cash Flow Screener - Liquidity Fundamentals
Screen ISHITADR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -4 | 2 | -3 | 3 | -1 | 1 | 1 | 1 | 1 | 0 |
| Investing Activities | -1 | 0 | 1 | -1 | 3 | -1 | -1 | -1 | -1 | 0 |
| Financing Activities | 4 | -1 | 1 | 0 | 0 | 0 | 0 | 0 | -1 | 1 |
| Net Cash Flow | 0 | 1 | -1 | 2 | 2 | 0 | 0 | 0 | -1 | 1 |
Screen ISHITADR shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 49.91% | 49.92% | 49.96% | 49.42% | 49.80% | 49.80% | 49.85% | 49.38% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.38% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 46.89% | 46.76% | 46.63% | 47.48% | 47.51% | 47.17% | 46.89% | 44.17% |
| Other Holding | 3.20% | 3.33% | 3.42% | 3.09% | 2.69% | 3.03% | 3.27% | 6.06% |
| Shareholder Count | 5,398 | 5,341 | 5,320 | 5,351 | 5,272 | 5,555 | 5,412 | 4,899 |
Ishita Drugs & Indus Dividend Screener - Share Yield Analysis
Screen ISHITADR dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Ishita Drugs & Indus Index Membership - Market Screener Classification
Screen ISHITADR by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Ishita Drugs & Indus Market Events Screener - Corporate Actions
Screen ISHITADR market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 8.66% | ||
| Annual General Meeting | NA | -3.22% | ||
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -0.40% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -9.29% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -2.94% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -12.35% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 1.31% |
Ishita Drugs & Indus Competitors Screener - Peer Comparison
Screen ISHITADR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 424,634 | 39.93 | 54,729 | 9.71% | 10,980 | 49.55 |
| Divis Laboratories | 172,860 | 69.20 | 9,712 | 18.67% | 2,191 | 56.33 |
| Torrent Pharmaceuticals | 129,151 | 60.10 | 11,539 | 6.99% | 1,911 | 61.47 |
| Cipla | 122,205 | 22.55 | 28,410 | 7.12% | 5,291 | 49.47 |
| Dr Reddys Laboratories | 107,114 | 18.60 | 33,741 | 16.73% | 5,725 | 60.05 |
| Lupin | 97,120 | 22.34 | 22,910 | 13.74% | 3,306 | 65.28 |
| Zydus Life Science | 92,392 | 18.40 | 23,511 | 18.55% | 4,615 | 40.07 |
| Mankind Pharma | 90,241 | 50.59 | 12,744 | 20.90% | 2,007 | 45.53 |
| Aurobindo Pharma | 71,119 | 20.79 | 32,346 | 9.43% | 3,484 | 59.88 |
| Alkem Laboratories | 67,243 | 27.59 | 13,458 | 3.70% | 2,216 | 49.80 |
Ishita Drugs & Indus Company Announcements - News Screener
Screen ISHITADR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-10 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011 | View |
| 2025-12-04 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011 | View |
| 2025-12-02 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011 | View |
| 2025-12-02 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011 | View |
| 2025-11-22 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011 | View |
| 2025-11-20 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011 | View |
| 2025-11-20 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011 | View |
| 2025-11-19 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares & Takeovers) Regulations 2011 | View |
| 2025-11-11 | Outcome Of Board Meeting Held On 11Th November 2025 | View |
| 2025-11-11 | Board Meeting Outcome for Outcome Of Board Meeting Held On 11Th November 2025 | View |
| 2025-11-05 | Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Quarter Ended 30Th September 2025 | View |
| 2025-10-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-01 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | View |
| 2025-10-01 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-10-01 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-29 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-25 | Closure of Trading Window | View |
| 2025-09-17 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011 | View |
| 2025-09-05 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011 | View |
| 2025-09-05 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011 | View |